Tony Berberabe, MPH

AKY-1189 gains fast track designation in urothelial cancer.

The LITESPARK-024 trial showed a manageable safety profile for belzutifan and palbociclib in advanced RCC, but the response rate did not exceed that of historical single-agent belzutifan.

Findings from the phase 3 LITESPARK-011 trial favored belzutifan/lenvatinib vs cabozantinib in PFS and ORR.

An integrated analysis of the RETAIN-1 and RETAIN-2 trials demonstrates that circulating tumor DNA is a powerful prognostic indicator for metastatic recurrence in muscle-invasive bladder cancer.

Neoadjuvant enfortumab vedotin plus pembrolizumab significantly improved event-free survival and overall survival compared with gemcitabine plus cisplatin.

Findings from the phase 1 PAnTHA study demonstrate that actinium-225 was well tolerated with encouraging responses in patients with metastatic castration-resistant prostate cancer.

The phase 2 BRCAAway trial demonstrated that abiraterone acetate, prednisone, and olaparib significantly improves progression-free survival and overall survival compared with either agent used alone or sequentially in patients with metastatic castration-resistant prostate cancer harboring BRCA1/2 or ATM alterations.

Highlights from the 2026 ASCO Genitourinary Cancer Symposium featuring key presentations in bladder, kidney, prostate, and rare cancers.

The FDA granted breakthrough therapy designation to Rybrevant Faspro based on data from the phase 1b/2 OrigAMI-4 study (NCT06385080).

The 5-mg dose of oxybutynin reduced the frequency and severity of hot flashes in men with prostate cancer undergoing treatment with androgen-deprivation therapy compared with placebo.

The IMMUNEBOOST-HPV trial investigated whether adding nivolumab (Opdivo) immunotherapy before standard chemoradiation could improve outcomes for patients with high-risk oropharyngeal cancer.

New ASCO Living Guidelines on prostate cancer emphasize first-line therapies, bone protection, and the growing role of genetic testing.

A novel blood based surveillance test using artificial intelligence and next-generation sequencing identified relapse a median of 41 days before clinical detection in patients with AML or MDS following transplant.

A recent white paper determines that the link between GLP-1 agonist inhibitors and thyroid cancer is unconvincing.

NPX372 received Investigational New Drug Clearance from the FDA, allowing for clinical development.

New research defines distinct therapeutic strategies for the 2 classes of CALR mutations in myelofibrosis, with implications for future patient management and clinical trial design.

Post hoc data suggest Orca-T may boost survival and cut non-relapse mortality after allogeneic stem cell transplant in MDS and leukemias, pending phase 3 validation.

During his presentation at the 4th Annual Miami Cancer Institute Precision Oncology Symposium, Petros Grivas, MD, PhD, FASCO, provided a detailed roadmap for community oncologists with an emphasis on precision medicine.

New research uncovers how genetic ancestry influences head and neck cancer biology, paving the way for personalized treatment strategies and improved patient outcomes.

A new clinical trial evaluates survival outcomes for recurrent head and neck cancer, comparing surgery with neoadjuvant chemotherapy and immunotherapy.

Explore the evolving landscape of myelodysplastic syndromes management, highlighting personalized therapies and novel treatment strategies for better patient outcomes.

FDA designates OPN-2853 as an orphan drug for myelofibrosis, showing promising results in spleen size reduction and safety in clinical trials.

FDA fast-tracks BNT113, an mRNA immunotherapy, for treating HPV16+ head and neck cancer, enhancing immune responses alongside pembrolizumab.

Practice-changing 2025 breast cancer trial updates spotlight giredestrant, tucatinib maintenance, and ribociclib in key subtypes, boosting disease control with manageable safety.

The FDA reviews ropeginterferon alfa-2b-njft for essential thrombocythemia, showing promising efficacy in clinical trials for patients.

Emerging evidence of the benefit of antibody-drug conjugates in diffuse large B-cell lymphoma continues to make a strong case for the agents to be used in earlier lines of therapy.